Phase II Trial Assessing the Ability of Neoadjuvant Chemotherapy With or Without Second-Look Surgery to Eliminate Measurable Disease for Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study.

J Clin Oncol

Stewart Goldman, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL; Eric Bouffet, The Hospital for Sick Children, Toronto, ON, Canada; Paul G. Fisher, Lucile Packard Children's Hospital Stanford, Palo Alto; Cynthia S. Kretschmar, Children's Hospital Los Angeles, Los Angeles; Tianni Zhou, California State University, Long Beach; Allen B. Buxton, Children's Oncology Group, Monrovia, CA; Jeffrey C. Allen and Bernadine Donahue, New York University Langone Medical Center, New York, NY; Patricia L. Robertson, University of Michigan C.S. Mott Children's Hospital, Ann Arbor; Paul J. Chuba, St. John Hospital and Medical Center, Grosse Pointe, MI; and Ian F. Pollack, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA.

Published: August 2015

Purpose: This phase II trial evaluated the effect of neoadjuvant chemotherapy with or without second-look surgery before craniospinal irradiation on response rates and survival outcomes in children with newly diagnosed non-germinomatous germ cell tumors.

Patients And Methods: Induction chemotherapy consisted of six cycles of carboplatin/etoposide alternating with ifosfamide/etoposide. Patients demonstrating less than complete response after induction chemotherapy were encouraged to undergo second-look surgery. Patients who did not achieve complete response or partial response after chemotherapy with or without second-look surgery proceeded to high-dose chemotherapy with thiotepa and etoposide and autologous peripheral blood stem-cell rescue before craniospinal irradiation.

Results: The study included 102 patients treated between January 2004 and July 2008. Median age was 12 years, and 76% were male; 53.9% had pineal region masses, and 23.5% had suprasellar lesions. Sixty-nine percent of patients achieved complete response or partial response with neoadjuvant chemotherapy. At 5 years, event-free survival was 84% ± 4% (SE) and overall survival was 93% ± 3%. During the median follow-up of 5.1 years, 16 patients recurred or progressed, with seven deaths after relapse. No deaths were attributed to therapy-related toxicity. Relapse occurred at the site of primary disease in 10 patients, at a distant site in three patients, or both in one patient. In two patients, progression was detected by marker increase alone. Increased serum α-fetoprotein was a negative prognostic variable. Histologic subtype and increase of beta-human chorionic gonadotropin were not significantly correlated with worse outcomes.

Conclusion: Neoadjuvant chemotherapy with or without second-look surgery achieved high response rates contributing to excellent survival outcomes in children with newly diagnosed non-germinomatous germ cell tumors. This regimen should be included as a backbone for further studies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4507465PMC
http://dx.doi.org/10.1200/JCO.2014.59.5132DOI Listing

Publication Analysis

Top Keywords

second-look surgery
20
neoadjuvant chemotherapy
16
chemotherapy second-look
16
germ cell
12
complete response
12
phase trial
8
chemotherapy
8
cell tumors
8
response rates
8
survival outcomes
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!